IRCT201601102394N20 - Bifidobacterium longum R0175 + Fluoxetine + Lactobacillus helveticus R0052 & Major depressive disorder / Major Depression / Depressive episode (MDD)

Background

Probiotics might enhance mood; however, their effectiveness as an additional treatment for major depressive disorder (MDD) remains unclear (1)

Study overview

The study is a randomized, double-blind, placebo-controlled clinical trial that investigates the effects of Bifidobacterium longum R0175 at a concentration of 3 × 10^9 CFU/g combined with either 10 or 20 mg of fluoxetine daily, along with Lactobacillus helveticus R0052 at a concentration of 3 × 10^9 CFU/g. Alternatively, it examines the effects of just 10 or 20 mg of fluoxetine daily. This trial analyzes 44 patients who have been diagnosed with Major Depressive Disorder, Major Depression, or a Depressive Episode (MDD) and spans a period of eight weeks (1)

Primary outcome measures

Depression severity, evaluated using the 24-item …